TDMS Study 96020-01 Pathology Tables
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 09:43:49
FINAL #1
Facility: Battelle Columbus Laboratory
Chemical CAS #: TEFBINARYMIX
Lock Date: 03/27/02
Cage Range: All
Reasons For Removal: 25018 Dosing Accident 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include 001 0 NG / 0 UG
Include 002 10 NG / 10 UG
Include 003 100 NG /100 UG
Include 005 300 NG /300 UG
Include 007 1000 NG/1000 UG
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 09:43:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 98 86 98 98 98
Early Deaths
Moribund Sacrifice 22 19 24 19 20
Natural Death 8 12 6 10 7
Dosing Accident 1 1 1 2
Survivors
Terminal Sacrifice 22 21 22 24 24
Animals Examined Microscopically 53 53 53 53 53
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (53) (53) (52) (53) (52)
Cyst 1 (2%)
Perforation 1 (2%) 2 (4%)
Muscularis, Inflammation 3 (6%) 1 (2%) 1 (2%) 3 (6%) 3 (6%)
Periesophageal Tissue, Hemorrhage 1 (2%)
Periesophageal Tissue, Inflammation 1 (2%) 1 (2%)
Intestine Large, Colon (53) (53) (53) (52) (49)
Hyperplasia, Lymphoid 1 (2%)
Parasite Metazoan 2 (4%)
Intestine Large, Rectum (53) (53) (53) (53) (50)
Metaplasia, Squamous 1 (2%)
Parasite Metazoan 2 (4%) 1 (2%) 3 (6%)
Intestine Large, Cecum (53) (53) (53) (52) (49)
Mineralization 1 (2%)
Intestine Small, Jejunum (53) (53) (52) (52) (49)
Hyperplasia, Lymphoid 1 (2%) 2 (4%) 1 (2%)
Ulcer 1 (2%)
Intestine Small, Ileum (53) (53) (52) (52) (49)
Hyperplasia, Lymphoid 1 (2%)
Liver (53) (53) (52) (52) (51)
Angiectasis 3 (6%) 1 (2%) 1 (2%) 2 (4%) 5 (10%)
Basophilic Focus 9 (17%) 7 (13%) 8 (15%) 2 (4%) 3 (6%)
Basophilic Focus, Multiple 13 (25%) 15 (28%) 6 (12%) 1 (2%) 3 (6%)
Cholangiofibrosis 1 (2%) 7 (13%) 39 (76%)
Clear Cell Focus 3 (6%) 2 (4%) 2 (4%) 3 (6%) 1 (2%)
Clear Cell Focus, Multiple 6 (11%) 1 (2%) 1 (2%)
Eosinophilic Focus 7 (13%) 8 (15%) 4 (8%) 7 (13%) 1 (2%)
Eosinophilic Focus, Multiple 7 (13%) 8 (15%) 26 (50%) 33 (63%) 17 (33%)
Fatty Change, Diffuse 3 (6%) 1 (2%) 9 (17%) 31 (60%) 38 (75%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 09:43:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Fatty Change, Focal 3 (6%) 4 (8%) 7 (13%) 1 (2%) 12 (24%)
Hematopoietic Cell Proliferation 27 (51%) 29 (55%) 30 (58%) 19 (37%) 11 (22%)
Hepatodiaphragmatic Nodule 2 (4%)
Hyperplasia, Nodular 2 (4%) 24 (46%) 42 (82%)
Inflammation 44 (83%) 41 (77%) 46 (88%) 48 (92%) 46 (90%)
Metaplasia 1 (2%)
Mixed Cell Focus 7 (13%) 3 (6%) 4 (8%) 2 (4%) 1 (2%)
Mixed Cell Focus, Multiple 19 (36%) 19 (36%) 26 (50%) 24 (46%) 2 (4%)
Necrosis 4 (8%) 8 (15%) 5 (10%) 4 (8%) 20 (39%)
Pigmentation 2 (4%) 5 (9%) 38 (73%) 50 (96%) 50 (98%)
Toxic Hepatopathy 2 (4%) 34 (65%) 48 (92%) 49 (96%)
Bile Duct, Cyst 4 (8%) 3 (6%) 1 (2%) 5 (10%) 23 (45%)
Bile Duct, Dilatation 1 (2%)
Bile Duct, Fibrosis 1 (2%) 3 (6%) 3 (6%) 4 (8%)
Bile Duct, Hyperplasia 8 (15%) 2 (4%) 9 (17%) 29 (56%) 46 (90%)
Centrilobular, Degeneration 5 (9%) 7 (13%) 2 (4%) 4 (8%) 3 (6%)
Centrilobular, Fibrosis 1 (2%) 1 (2%)
Hepatocyte, Hypertrophy 1 (2%) 7 (13%) 17 (33%) 33 (63%) 50 (98%)
Hepatocyte, Multinucleated 14 (27%) 46 (88%) 48 (94%)
Oval Cell, Hyperplasia 2 (4%) 2 (4%) 15 (29%) 39 (75%) 46 (90%)
Portal, Fibrosis 7 (13%) 34 (67%)
Serosa, Inflammation, Chronic Active 1 (2%)
Mesentery (47) (47) (46) (47) (42)
Artery, Inflammation, Chronic Active 1 (2%) 1 (2%) 1 (2%) 2 (4%) 4 (10%)
Fat, Necrosis 2 (4%) 2 (4%) 1 (2%)
Oral Mucosa (12) (11) (25) (30) (36)
Gingival, Hyperplasia, Squamous 8 (67%) 8 (73%) 18 (72%) 22 (73%) 24 (67%)
Pharyngeal, Inflammation 1 (3%)
Pancreas (53) (53) (52) (52) (50)
Inflammation, Chronic Active 3 (6%) 3 (6%) 1 (2%) 4 (8%)
Acinus, Atrophy 2 (4%) 1 (2%) 1 (2%) 8 (16%)
Acinus, Hyperplasia 2 (4%) 1 (2%)
Acinus, Vacuolization Cytoplasmic 7 (13%) 40 (80%)
Artery, Inflammation, Chronic Active 1 (2%) 2 (4%) 2 (4%)
Duct, Dilatation 1 (2%)
Salivary Glands (53) (51) (52) (50) (52)
Inflammation, Chronic Active 1 (2%)
Stomach, Forestomach (53) (53) (52) (52) (51)
Hyperkeratosis 1 (2%) 2 (4%)
Hyperplasia, Squamous 1 (2%) 1 (2%) 2 (4%) 7 (13%) 8 (16%)
Inflammation 1 (2%) 1 (2%)
Mineralization 1 (2%) 1 (2%)
Ulcer 1 (2%) 2 (4%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 09:43:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Stomach, Glandular (53) (53) (52) (52) (51)
Cyst 1 (2%)
Ectopic Tissue 1 (2%)
Erosion 1 (2%) 2 (4%)
Inflammation, Chronic Active 1 (2%)
Mineralization 4 (8%) 3 (6%) 3 (6%) 1 (2%)
Ulcer 1 (2%)
Tooth (23) (14) (33) (35) (31)
Peridontal Tissue, Inflammation 23 (100%) 14 (100%) 33 (100%) 35 (100%) 31 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (53) (53) (52) (53) (52)
Aorta, Mineralization 1 (2%)
Heart (53) (52) (52) (53) (52)
Cardiomyopathy 22 (42%) 19 (37%) 22 (42%) 26 (49%) 15 (29%)
Fibrosis 1 (2%)
Hemorrhage 1 (2%)
Inflammation, Chronic Active 1 (2%) 1 (2%)
Thrombosis 1 (2%)
Coronary Artery, Inflammation, Chronic Active 1 (2%) 6 (12%)
Pericardium, Necrosis 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (53) (53) (52) (52) (51)
Angiectasis 17 (32%) 26 (49%) 33 (63%) 23 (44%) 5 (10%)
Atrophy 3 (6%) 35 (69%)
Degeneration, Cystic 13 (25%) 12 (23%) 13 (25%) 14 (27%) 16 (31%)
Hematopoietic Cell Proliferation 1 (2%)
Hyperplasia 11 (21%) 18 (34%) 23 (44%) 25 (48%) 18 (35%)
Hypertrophy 47 (89%) 38 (72%) 44 (85%) 41 (79%) 32 (63%)
Necrosis 1 (2%) 1 (2%)
Vacuolization Cytoplasmic 11 (21%) 12 (23%) 14 (27%) 10 (19%) 13 (25%)
Adrenal Medulla (52) (53) (52) (52) (51)
Hyperplasia 15 (29%) 13 (25%) 14 (27%) 13 (25%) 3 (6%)
Islets, Pancreatic (53) (53) (52) (52) (50)
Hyperplasia 1 (2%)
Parathyroid Gland (45) (47) (46) (47) (46)
Hyperplasia 1 (2%)
Pituitary Gland (53) (53) (53) (52) (52)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 09:43:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Angiectasis 17 (32%) 20 (38%) 15 (28%) 17 (33%) 1 (2%)
Cyst 1 (2%) 3 (6%)
Cytoplasmic Alteration 3 (6%)
Inflammation 1 (2%)
Vacuolization Cytoplasmic 1 (2%)
Pars Distalis, Hyperplasia 13 (25%) 13 (25%) 19 (36%) 20 (38%) 13 (25%)
Pars Intermedia, Hyperplasia 2 (4%)
Thyroid Gland (53) (53) (51) (52) (52)
C-Cell, Hyperplasia 15 (28%) 19 (36%) 22 (43%) 12 (23%) 15 (29%)
Follicle, Cyst 2 (4%)
Follicular Cell, Hypertrophy 14 (26%) 17 (32%) 34 (67%) 35 (67%) 42 (81%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (53) (53) (53) (53) (50)
Inflammation 45 (85%) 49 (92%) 46 (87%) 40 (75%) 23 (46%)
Duct, Cyst 38 (72%) 40 (75%) 48 (91%) 43 (81%) 43 (86%)
Ovary (53) (53) (52) (52) (49)
Atrophy 45 (85%) 44 (83%) 45 (87%) 43 (83%) 16 (33%)
Cyst 14 (26%) 7 (13%) 17 (33%) 14 (27%) 13 (27%)
Inflammation, Chronic Active 1 (2%) 1 (2%) 1 (2%)
Inflammation, Suppurative 1 (2%)
Oviduct (1) (1) (2) (3)
Cyst 1 (100%) 1 (100%) 2 (100%)
Inflammation, Chronic Active 1 (100%) 3 (100%)
Uterus (53) (53) (53) (52) (50)
Adenomyosis 1 (2%) 1 (2%)
Hemorrhage 1 (2%)
Hyperplasia 1 (2%)
Inflammation, Chronic Active 3 (6%) 1 (2%) 7 (13%) 2 (4%)
Inflammation, Suppurative 3 (6%) 5 (9%) 8 (15%) 10 (19%) 5 (10%)
Metaplasia, Squamous 27 (51%) 30 (57%) 35 (66%) 36 (69%) 14 (28%)
Ulcer 1 (2%)
Endometrium, Hyperplasia, Cystic 28 (53%) 23 (43%) 34 (64%) 18 (35%) 12 (24%)
Vagina (1) (1) (1) (1)
Inflammation 1 (100%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 09:43:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (53) (53) (53) (53) (53)
Atrophy 1 (2%)
Degeneration 1 (2%)
Hyperplasia 39 (74%) 38 (72%) 42 (79%) 48 (91%) 49 (92%)
Lymph Node (4) (7) (2) (7) (14)
Angiectasis 1 (14%) 1 (7%)
Inguinal, Hyperplasia, Plasma Cell 1 (14%)
Lumbar, Ectasia 4 (100%) 4 (57%) 1 (14%)
Lumbar, Hemorrhage 2 (29%)
Lumbar, Hyperplasia 1 (14%)
Lumbar, Hyperplasia, Plasma Cell 4 (100%) 1 (14%)
Mediastinal, Ectasia 3 (21%)
Mediastinal, Hemorrhage 1 (14%) 2 (14%)
Mediastinal, Hyperplasia, Histiocytic 1 (14%) 1 (14%) 3 (21%)
Mediastinal, Hyperplasia, Lymphoid 1 (14%)
Mediastinal, Hyperplasia, Plasma Cell 2 (14%)
Pancreatic, Hyperplasia, Histiocytic 1 (14%) 3 (21%)
Pancreatic, Hyperplasia, Plasma Cell 1 (7%)
Pancreatic, Pigmentation 1 (14%) 1 (7%)
Renal, Ectasia 1 (14%) 1 (50%) 1 (14%) 1 (7%)
Renal, Hemorrhage 1 (50%)
Renal, Hyperplasia, Histiocytic 1 (14%) 2 (14%)
Renal, Hyperplasia, Lymphoid 1 (7%)
Renal, Hyperplasia, Plasma Cell 1 (14%) 1 (14%)
Lymph Node, Mandibular (53) (51) (52) (50) (51)
Congestion 1 (2%)
Ectasia 3 (6%) 6 (12%) 3 (6%) 6 (12%)
Hemorrhage 1 (2%) 1 (2%)
Hyperplasia, Lymphoid 1 (2%) 2 (4%) 3 (6%) 2 (4%) 5 (10%)
Hyperplasia, Plasma Cell 37 (70%) 37 (73%) 40 (77%) 36 (72%) 31 (61%)
Lymph Node, Mesenteric (53) (53) (52) (52) (49)
Hemorrhage 1 (2%)
Hyperplasia, Histiocytic 1 (2%) 2 (4%)
Hyperplasia, Lymphoid 1 (2%) 1 (2%)
Inflammation, Chronic Active 1 (2%)
Spleen (53) (53) (52) (52) (50)
Fibrosis 1 (2%)
Hematopoietic Cell Proliferation 51 (96%) 51 (96%) 49 (94%) 47 (90%) 44 (88%)
Hyperplasia 1 (2%)
Pigmentation 47 (89%) 46 (87%) 43 (83%) 51 (98%) 46 (92%)
Lymphoid Follicle, Atrophy 2 (4%) 4 (8%) 5 (10%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 09:43:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Red Pulp, Atrophy 1 (2%) 1 (2%) 5 (10%)
Thymus (53) (50) (48) (50) (51)
Atrophy 33 (62%) 33 (66%) 43 (90%) 42 (84%) 49 (96%)
Cyst 1 (2%)
Hemorrhage 1 (2%) 3 (6%) 1 (2%)
Hyperplasia, Lymphoid 2 (4%)
Inflammation 1 (2%)
Epithelial Cell, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (53) (53) (52) (53) (52)
Cyst 3 (6%) 2 (4%) 2 (4%) 3 (6%) 1 (2%)
Hyperplasia 29 (55%) 29 (55%) 25 (48%) 22 (42%) 3 (6%)
Inflammation, Granulomatous 5 (9%) 4 (8%) 3 (6%)
Duct, Cyst 1 (2%)
Skin (53) (53) (53) (53) (53)
Angiectasis 1 (2%)
Cyst Epithelial Inclusion 1 (2%)
Fibrosis 1 (2%)
Inflammation 1 (2%) 1 (2%)
Ulcer 2 (4%) 1 (2%)
Dermis, Fibrosis 1 (2%)
Epidermis, Hyperplasia 1 (2%)
Subcutaneous Tissue, Inflammation 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (1) (1) (1)
Hemorrhage 1 (100%)
Inflammation 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (53) (53) (53) (52) (52)
Hemorrhage 1 (2%) 1 (2%)
Hydrocephalus 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 09:43:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (53) (53) (52) (53) (52)
Hemorrhage 1 (2%)
Infiltration Cellular, Histiocyte 47 (89%) 41 (77%) 47 (90%) 46 (87%) 45 (87%)
Inflammation 8 (15%) 5 (9%) 2 (4%) 4 (8%) 1 (2%)
Metaplasia, Squamous 1 (2%) 2 (4%) 11 (21%)
Mineralization 1 (2%) 1 (2%)
Alveolar Epithelium, Hyperplasia 23 (43%) 20 (38%) 17 (33%) 5 (9%) 5 (10%)
Alveolar Epithelium, Metaplasia, Bronchiolar 6 (11%) 23 (44%) 34 (64%) 32 (62%)
Bronchiole, Hyperplasia 1 (2%)
Mediastinum, Hemorrhage 1 (2%)
Mediastinum, Necrosis 1 (2%)
Serosa, Inflammation 1 (2%)
Nose (53) (53) (53) (53) (53)
Hyperplasia 1 (2%)
Inflammation 22 (42%) 13 (25%) 13 (25%) 13 (25%) 31 (58%)
Glands, Hyperplasia 8 (15%)
Olfactory Epithelium, Degeneration 1 (2%) 2 (4%)
Olfactory Epithelium, Metaplasia 4 (8%) 3 (6%) 5 (9%) 6 (11%) 15 (28%)
Respiratory Epithelium, Hyperplasia 10 (19%) 5 (9%) 7 (13%) 11 (21%) 20 (38%)
Respiratory Epithelium, Metaplasia 1 (2%)
Respiratory Epithelium, Vacuolization
Cytoplasmic 1 (2%)
Trachea (53) (53) (52) (53) (52)
Inflammation 1 (2%)
Peritracheal Tissue, Hemorrhage 1 (2%)
Peritracheal Tissue, Inflammation 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (53) (53) (53) (52) (52)
Anterior Chamber, Ciliary Body, Cornea,
Inflammation 1 (2%) 3 (6%)
Cornea, Inflammation 1 (2%)
Retina, Atrophy 1 (2%) 3 (6%) 4 (8%) 2 (4%) 5 (10%)
Harderian Gland (53) (53) (53) (52) (52)
Inflammation 20 (38%) 14 (26%) 16 (30%) 14 (27%) 16 (31%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (53) (53) (52) (52) (51)
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 09:43:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Accumulation, Hyaline Droplet 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Calculus Gross Observation 1 (2%)
Calculus Micro Observation Only 7 (13%) 4 (8%) 1 (2%) 4 (8%) 1 (2%)
Casts Protein 2 (4%) 1 (2%)
Cyst 1 (2%) 1 (2%) 1 (2%)
Infarct 1 (2%) 1 (2%)
Inflammation, Chronic Active 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Inflammation, Suppurative 5 (9%) 3 (6%) 1 (2%) 5 (10%) 1 (2%)
Mineralization 42 (79%) 38 (72%) 39 (75%) 42 (81%) 35 (69%)
Necrosis 1 (2%)
Nephropathy 29 (55%) 22 (42%) 29 (56%) 34 (65%) 43 (84%)
Pigmentation 1 (2%) 3 (6%) 7 (13%) 35 (69%)
Pelvis, Dilatation 1 (2%) 2 (4%) 1 (2%)
Pelvis, Inflammation 3 (6%) 4 (8%) 3 (6%) 5 (10%)
Renal Tubule, Degeneration 1 (2%) 2 (4%) 1 (2%)
Transitional Epithelium, Hyperplasia 2 (4%) 2 (4%) 4 (8%) 11 (21%) 6 (12%)
Ureter (1) (1) (1) (1)
Inflammation 1 (100%) 1 (100%)
Mineralization 1 (100%)
Transitional Epithelium, Hyperplasia 1 (100%) 1 (100%)
Urinary Bladder (53) (53) (53) (52) (50)
Inflammation 7 (13%) 8 (15%) 5 (9%) 7 (13%)
Transitional Epithelium, Hyperplasia 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------